Artivion

Yahoo Finance • last month

Liberty All-Star® Growth Fund, Inc. October 2025 Monthly Update

BOSTON, November 14, 2025--(BUSINESS WIRE)--Below is the October 2025 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG). Liberty All-Star Growth Fund, Inc. Ticker: ASG Monthly Update, October 2025 Investment Approac... Full story

Yahoo Finance • 2 months ago

Strong Results and Improved Guidance Lifted Artivion (AORT)

Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets continued their upward traject... Full story

Yahoo Finance • 4 months ago

Artivion CEO Mackin sells $528k in shares

Artivion (NASDAQ:AORT) President and CEO James P. Mackin sold 12,500 shares of common stock on August 15, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sale comes as the stock trades near its 52-week h... Full story

Yahoo Finance • 5 months ago

Artivion price target raised to $45 from $32 at Needham

Needham analyst Mike Matson raised the firm’s price target on Artivion (AORT) to $45 from $32 and keeps a Buy rating on the shares. The company’s constant currency revenue growth improved to 14.6% in Q2 from 3.6% in Q1, driven by strong On... Full story

Yahoo Finance • 5 months ago

Artivion raises 2025 revenue guidance to $435M–$443M as On-X and stent grafts drive double-digit growth

Earnings Call Insights: Artivion, Inc. (AORT) Q2 2025 MANAGEMENT VIEW * CEO Pat MacKin reported "strong business momentum continued through the second quarter as we delivered total constant currency revenue growth of over 14% and adjus... Full story

Yahoo Finance • 5 months ago

Artivion stock price target raised to $41 from $35 at Canaccord on strong Q2

Investing.com - Canaccord Genuity raised its price target on Artivion Inc. (NYSE:AORT) to $41.00 from $35.00 on Friday, maintaining a Buy rating following the company’s strong second-quarter performance. The medical device company, with a... Full story

Yahoo Finance • 5 months ago

[Latest] Global Cardiac Tissue Engineering Market Size/Share Worth USD 2,943.92 Million by 2034 at a 16.65% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Cardiac Tissue Engineering Market size & share revenue was valued at approximately U... Full story

Yahoo Finance • 5 months ago

Tandem Diabetes, Solventum, LeMaitre, UFP Technologies, and Artivion Stocks Trade Down, What You Need To Know

What Happened? A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White... Full story

Yahoo Finance • 5 months ago

Artivion Inc stock reaches 52-week high at 32.38 USD

Artivion Inc’s stock has reached a 52-week high, hitting 32.38 USD, marking a significant milestone for the $1.51 billion market cap company. According to InvestingPro analysis, the stock appears to be trading above its Fair Value, with an... Full story

Yahoo Finance • 6 months ago

Canaccord Genuity initiates Artivion stock with buy rating on aortic repair bets

Canaccord Genuity initiated coverage on Artivion Inc. (NYSE: AORT) with a buy rating and a $35.00 price target on Tuesday. The research firm cited the cardiac surgery company’s strategic investments in aortic arch repair that are "on the v... Full story

Yahoo Finance • 2 years ago

Artivion to Participate in Upcoming Investor Conferences

ATLANTA, Nov. 8, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. (PRNewsfoto/Artivio... Full story